Panobacumab (TAB-105)

Anti-B. anthracis anthrax protective antigen (PA) Recombinant Antibody (Aerumab 11) TAB-105 1mg Please Inquiry


  • Product Overview
  • Recombinant monoclonal antibody to P. aeruginosa. Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against P. aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
  • Target
  • P. aeruginosa serotype IATS O11
  • Type
  • IgM - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • P. aeruginosa
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, ICC and most other immunological methods.
  • CAS
  • 885053-97-4
  • Trade name
  • aerumab 11
  • Specific Activity
  • Tested positive against native P. aeruginosa antigen
  • Protein Construction
  • immunoglobulin M-kappa [P. aeruginosa serotype IATS O11], Homo sapiens monoclonal antibody with a Mus musculus J chain
  • Predicted N terminal
  • H chain: EEQVVES; L chain: DVVMTQS
  • Molecular Weight
  • 879900
  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Size
  • 1mg
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.


  • Introduction
  • This is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
  • Antigen Description
  • P. aeruginosa is Gram-negative, aerobic, rod-shaped bacteria with unipolar motility. An opportunistic human pathogen, P. aeruginosa is also an opportunistic pathogen of plants. P. aeruginosa bacteria are clinically important because they are resistant to most antibiotics and they are capable of surviving in conditions that few other organisms can tolerate. Pseudomonas is often encountered in hospital and clinical work because it is a major cause of hospital acquired (nosocomal) infections. Its main targets are immunocompromised individuals, burn victims, and individuals on respirators or with indwelling catheters. Additionally, these pathogens colonize the lungs of cystic fibrosis patients. P. aeruginosa is often identified by its pearlescent appearance and grape-like odor in vitro. Definitive clinical identification of P. aeruginosa includes identifying the production of both pyocyanin and fluorescein as well as its ability to grow at 42°C. P. aeruginosa is capable of growth in diesel and jet fuel, where it is known as hydrocarbon utilizing microorganisms (or "HUM bugs"), causing microbial corrosion. It creates dark gellish mats sometimes improperly called "algae".
  • Keywords
  • Pseudomonas aeruginosa; P Aeruginosa; P. Aeruginosa; IATS O11

Related Products

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us